Tempest Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2026 Special Meeting of Stockholders held by Tempest Therapeutics, Inc. on June 18, 2026. The filing details the final voting results for two proposals submitted to shareholders regarding the issuance of common stock pursuant to Nasdaq Rule 5635.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Shareholders approved two proposals to authorize the issuance of common stock upon the exercise of outstanding warrants:
- Proposal 1: Approval to issue up to 925,927 shares from Series A Warrants and 925,927 shares from Series B Warrants (issued in a March 2026 private placement).
- Votes For: 9,090,763
- Votes Against: 398,678
- Abstentions: 18,310
- Proposal 2: Approval to issue up to 2,344,828 shares from Common Warrants (issued in connection with an inducement offer in May 2026 for warrants originally issued in November 2025).
- Votes For: 9,091,165
- Votes Against: 398,276
- Abstentions: 18,310
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, or contingencies. The document serves strictly to report the submission of matters to a vote of security holders.
Key Facts for Investor Verification
- Confirm the total potential dilution from the approved warrant exercises (approximately 4.2 million shares).
- Verify the terms of the Series B Warrants issued in the March 20, 2026 private placement.
- Review the details of the May 28, 2026 letter agreement regarding the inducement offer for Common Warrants.
- Check subsequent filings for the actual exercise of these warrants and the resulting cash proceeds.